Education
About Us
Working with TipRanks
Follow Us
TransMedics Group Inc (TMDX)
NASDAQ:TMDX
TMDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$55.00 - $145.50
Previous CloseN/A
Volume1.17M
Average Volume (3M)989.15K
Market Cap
$3.66B
Enterprise Value$5.55B
Total Cash (Recent Filing)$400.57M
Total Debt (Recent Filing)$518.82M
Price to Earnings (P/E)55.5
Beta1.24
Next Earnings
Nov 11, 2025EPS Estimate
0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.92
Shares Outstanding34,090,355
10 Day Avg. Volume839,723
30 Day Avg. Volume989,154
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)9.06
Price to Sales (P/S)4.69
P/FCF Ratio-25.60
Enterprise Value/Market Cap1.52
Enterprise Value/Revenue10.45
Enterprise Value/Gross Profit17.48
Enterprise Value/Ebitda49.61
Forecast
1Y Price Target
$142.20Price Target Upside32.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Long-term Growth PotentialReforms focusing on rebuilding public trust in the system could help drive incremental growth in net new donor registrations over time, benefiting the company’s long-term outlook.
Market PositioningTransMedics is exceptionally well positioned to benefit as its combined offering has been the single largest catalyst of rising US liver, heart, and lung transplant volumes since 2022.
Organ Transplant DemandLiver transplants are expected to be the main growth driver for TransMedics, with market share increasing significantly.
Bears Say
Aviation Case DeclineThe aviation data shows a potential decline of ~16% in TMDX aviation cases, driven by a similar decline in daily flight volume and daily flight hours.
Short-term Revenue ProjectionsThird-quarter revenue could approximate $140 million, which is roughly 4% below the current Street estimate of $145.3 million.
Transplant Volume ChallengesThe SRTR data for August 2025 indicates that TMDX's transplant volumes were likely below the average monthly rate in 2Q25.
TransMedics Group News
TMDX FAQ
What was TransMedics Group Inc’s price range in the past 12 months?
TransMedics Group Inc lowest stock price was $55.00 and its highest was $145.50 in the past 12 months.
What is TransMedics Group Inc’s market cap?
TransMedics Group Inc’s market cap is $3.66B.
When is TransMedics Group Inc’s upcoming earnings report date?
TransMedics Group Inc’s upcoming earnings report date is Nov 11, 2025 which is in 28 days.
How were TransMedics Group Inc’s earnings last quarter?
TransMedics Group Inc released its earnings results on Jul 30, 2025. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.47.
Is TransMedics Group Inc overvalued?
According to Wall Street analysts TransMedics Group Inc’s price is currently Undervalued.
Does TransMedics Group Inc pay dividends?
TransMedics Group Inc does not currently pay dividends.
What is TransMedics Group Inc’s EPS estimate?
TransMedics Group Inc’s EPS estimate is 0.36.
How many shares outstanding does TransMedics Group Inc have?
TransMedics Group Inc has 34,090,355 shares outstanding.
What happened to TransMedics Group Inc’s price movement after its last earnings report?
TransMedics Group Inc reported an EPS of $0.92 in its last earnings report, beating expectations of $0.45. Following the earnings report the stock price went up 10.464%.
Which hedge fund is a major shareholder of TransMedics Group Inc?
Currently, no hedge funds are holding shares in TMDX
TransMedics Group Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$142.20 (32.54% Upside)
$142.20 (32.54% Upside)
Blogger Sentiment
Bullish
TMDX Sentiment 80%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 13.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-21.05%
12-Months-Change
Fundamentals
Return on Equity
28.21%
Trailing 12-Months
Asset Growth
17.39%
Trailing 12-Months
Company Description
TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TMDX Company Deck
TMDX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong financial performance with significant revenue and profit growth, successful FDA approvals, and raised guidance. However, there were challenges including a decline in OUS revenue and anticipated seasonality impacts, alongside addressing competitive noise. Overall, the positive highlights significantly outweighed the lowlights.View all TMDX earnings summariesTMDX Stock 12 Month Forecast
Average Price Target
$142.20
▲(32.54% Upside)
Technical Analysis
Ownership Overview
3.58% Insiders
40.60% Mutual Funds
22.51% Other Institutional Investors
9.92% Public Companies and Individual Investors